Marked insulin resistance in obese spontaneously hypertensive rat adipocytes is ameliorated by in vivo but not in vitro treatment with moxonidine

Journal of Pharmacology and Experimental Therapeutics

Volumn 320, Issue 2, 2007, Pages 845-852

  Sun, Zheng ^a   Ernsberger, Paul ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMIDAZOLIDINE DERIVATIVE; MOXONIDINE; PROTEIN KINASE B;

ADIPOCYTE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; GLUCOSE TRANSPORT; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; MALE; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT;

ADIPOCYTES; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCOSE; HYPERTENSION; IMIDAZOLES; INSULIN RESISTANCE; MALE; OBESITY; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, INBRED SHR;

EID: 33846420170     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.111153     Document Type: Article

References (31)

1. Anichkov DA, Shostak NA, and Schastnaya OV (2005) Comparison of rilmenidine and lisinopril on ambulatory blood pressure and plasma lipid and glucose levels in hypertensive women with metabolic syndrome. Curr Med Res Opin 21:113-119.
2. Chazova I, Almazov VA, and Shlyakhto E (2006) Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin. Diabetes Obes Metab 8:456-465.
3. Edwards L and Ernsberger P (2003) The I(1)-imidazoline receptor in PC12 pheochromocytoma cells reverses NGF-induced ERK activation and induces MKP-2 phosphatase. Brain Res 980:71-79.
4. Edwards L, Fishman D, Horowitz P, Bourbon N, Kester M, and Ernsberger P (2001) The I(1)-imidazoline receptor in PC12 pheochromocytoma cells activates protein kinases C, extracellular signal-regulated kinase (ERK) and c-jun N-terminal kinase (JNK). J Neurochem 79:931-940.
5. 1-imidazoline sites. J Pharmacol Exp Ther 264:172-182.
6. Ernsberger P, Ishizuka T, Liu S, Farrell CJ, Bedol D, Koletsky RJ, and Friedman JE (1999a) Mechanisms of antihyperglycemic effects of moxonidine in the obese spontaneously hypertensive Koletsky rat (SHROB). J Pharmacol Exp Ther 288:139-147.
7. Ernsberger P, Koletsky RJ, Collins LA, and Bedol DL (1996) Sympathetic nervous system in salt-sensitive and obese hypertension: amelioration of multiple abnormalities by a central sympatholytic agent. Cardiovasc Drugs Ther 10:275-282.
8. Ernsberger P, Koletsky RJ, and Friedman JE (1999b) Molecular pathology in the obese spontaneous hypertensive Koletsky rat: a model of syndrome X. Ann NY Acad Sci 892:272-288.
9. Friedman JE, Ishizuka T, Liu S, Farrell CJ, Bedol D, Koletsky RJ, Kaung HL, and Ernsberger P (1997) Reduced insulin receptor signaling in the obese spontaneously hypertensive Koletsky rat. Am J Physiol 273:E1014-E1023.
10. Haenni A and Lithell H (1999) Moxonidine improves insulin sensitivity in insulin-resistant hypertensives. J Hypertens 17 (Suppl 3):S29-S35.
11. Hanada M, Feng J, and Hemmings BA (2004) Structure, regulation and function of PKB/AKT-a major therapeutic target. Biochim Biophys Acta 1697:3-16.
12. He MM, Abraham TL, Lindsay TJ, Chay SH, Czeskis BA, and Shipley LA (2000) Metabolism and disposition of moxonidine in Fischer 344 rats. Drug Metab Dispos 28:446-459.
13. Henriksen EJ, Jacob S, Fogt DL, Youngblood EB, and Gödicke J (1997) Antihypertensive agent moxonidine enhances muscle glucose transport in insulin-resistant rats. Hypertension 30:1560-1565.
14. Hresko RC and Mueckler M (2005) mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem 280:40406-40416.
15. Jacob S, Klimm HJ, Rett K, Helsberg K, Haring HU, and Godicke J (2004) Effects of moxonidine vs. metoprolol on blood pressure and metabolic control in hypertensive subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes 112:315-322.
16. Kaan EC, Brückner R, Frohly P, Tulp M, Schäfer SG, and Ziegler D (1995) Effects of agmatine and moxonidine on glucose metabolism: an integrated approach towards pathophysiological mechanisms in cardiovascular metabolic disorders. Cardiovasc Risk Factors 5 (Suppl 1):19-27.
17. Karlsson HK, Zierath JR, Kane S, Krook A, Lienhard GE, and Wallberg-Henriksson H (2005) Insulin-stimulated phosphorylation of the Akt substrate AS160 is impaired in skeletal muscle of type 2 diabetic subjects. Diabetes 54:1692-1697.
18. Kava RA, West DB, Lukasik VA, Wypijewski C, Wojnar Z, Johnson PR, and Greenwood MRC (1992) The effects of gonadectomy on glucose tolerance of genetically obese (fa/fa) rats: influence of sex and genetic background. Int J Obes 16:103-111.
19. Koletsky S (1975) Pathologic findings and laboratory data in a new strain of obese hypertensive rats. Am J Pathol 80:129-142.
20. Lithell HO (1998) Insulin resistance and diabetes in the context of treatment of hypertension. Blood Press (Suppl 3):28-31.
21. Meredith PA and Reid JL (2004) Efficacy and tolerability of long-term rilmenidine treatment in hypertensive diabetic patients: a retrospective analysis of a general practice study. Am J Cardiovasc Drugs 4:195-200.
22. Morgan NG and Chan SL (2001) Imidazoline binding sites in the endocrine pancreas: can they fulfill their potential as targets for the development of new insulin secretagogues? Curr Pharm Des 7:1413-1431.
23. Osaki M, Oshimura M, and Ito H (2004) PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 9:667-676.
24. Penicaud L, Berthault MF, Morin J, Dubar M, Ktorza A, and Ferre P (1998) Rilmenidine normalizes fructose-induced insulin resistance and hypertension in rats. J Hypertens Suppl 16:S45-S49.
25. Rhinehart EK, Kalra SP, and Kalra PS (2004) Neuropeptidergic characterization of the leptin receptor mutated obese Koletsky rat. Regul Pept 119:3-10.
26. Velliquette RA and Ernsberger P (2003a) Contrasting metabolic effects of antihypertensive agents. J Pharmacol Exp Ther 307:1104-1111.
27. Velliquette RA and Ernsberger P (2003b) The role of I(1)-imidazoline and α(2)-adrenergic receptors in the modulation of glucose metabolism in the spontaneously hypertensive obese rat model of metabolic syndrome X. J Pharmacol Exp Ther 306:646-657.
28. Velliquette RA, Friedman JE, Shao J, Zhang BB, and Ernsberger P (2005) Therapeutic actions of an insulin receptor activator and a novel peroxisome proliferator-activated receptor gamma agonist in the spontaneously hypertensive obese rat model of metabolic syndrome X. J Pharmacol Exp Ther 314:422-430.
29. Velliquette RA, Kossover R, Previs SF, and Ernsberger P (2006) Lipid-lowering actions of imidazoline antihypertensive agents in metabolic syndrome X. Naunyn-Schmiedeberg's Arch Pharmacol 372:300-312.
30. Yakubu-Madus FE, Johnson WT, Zimmerman KM, Dananberg J, and Steinberg MI (1999) Metabolic and hemodynamic effects of moxonidine in the Zucker diabetic fatty rat model of type 2 diabetes. Diabetes 48:1093-1100.
31. Yki-Jarvinen H and Taskinen MR (1988) Interrelationships among insulin's antilipolytic and glucoregulatory effects and plasma triglycerides in nondiabetic and diabetic patients with endogenous hypertriglyceridemia. Diabetes 37:1271-1278.